AIM ImmunoTech is promoting a potential role for its experimental drug Ampligen in pancreatic cancer, where it could be combined with newer RAS-targeted treatments. A new investor presentation sets out the scientific rationale for pairing Ampligen’s immune-stimulating activity with daraxonrasib, a RAS inhibitor, but does not announce a clinical trial of the combination or report results from one.
The company also outlined milestones for its ongoing Phase 2 DURIPANC program, with topline results expected in the first quarter of 2027 and further clinical and immune-response analyses anticipated in the third quarter.
Key details
- AIM’s presentation, titled “The Ampligen Opportunity,” focuses on whether Ampligen (rintatolimod) might complement RAS-targeted therapies in pancreatic cancer, including daraxonrasib, which the release identifies by the trade name Rasonque.
- The proposed approach combines two different mechanisms: daraxonrasib targets RAS signaling pathways that drive tumor growth, while Ampligen is intended to stimulate innate and adaptive immune responses.
- AIM says the combination could potentially enhance or prolong clinical benefit from RAS-targeted treatment. That is a scientific rationale for further investigation, not evidence that the combination has been shown to work.
- The company points to previously reported clinical observations involving Ampligen as support for more research in pancreatic cancer. The announcement does not provide details of those observations.
- The Phase 2 DURIPANC program is ongoing. AIM expects topline results in Q1 2027, followed by additional clinical and immune-response analyses in Q3 2027.
- CEO Thomas K. Equels described daraxonrasib as a promising development and said he sees potential in combining it with Ampligen. His comments reflect the company’s view of the opportunity, not a clinical finding or regulatory determination.
What changes—and what does not
The announcement is about AIM’s research and investment narrative around Ampligen; it does not disclose a new financing, partnership, regulatory decision, or change in management. Nor does it announce that Ampligen and daraxonrasib are being tested together. The disclosed 2027 milestones relate to DURIPANC, while the proposed combination remains a rationale for further investigation.